Valneva SE
Business
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines addressing unmet infectious-disease needs. It offers proprietary travel vaccines (IXCHIQ, IXIARO/JESPECT, DUKORAL), third-party-distributed vaccines, and a clinical pipeline including VLA15 (Lyme), S4V2 (Shigella), VLA1601 (Zika) and other candidates. Its business is organized across commercial vaccine sales, clinical development and regulatory programs, and multi-site manufacturing and quality operations. Valneva markets and distributes products primarily in the United States, Canada and Europe and sells through its own commercial infrastructure, government contracts, and distribution partners.
Summary from filing dated 2025-03-24
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-115.19M |
| Total assets | $398.84M |
| Total liabilities | $292.67M |
| Stockholders' equity | — |
| Operating cash flow | — |